This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
5 Dec 2011

Russian Drugmakers Question Pricing Strategy

Russian pharmaceutical industry has questioned the country's list of vital and essential drugs (ZHMVLP) that forbids price increases.

Russia's pharmaceutical companies have questioned the country's list of vital and essential drugs (ZHMVLP) that forbids price increases, and have asked prime minister Vladimir Putin to resolve the issue.

 

The list will come into effect at the start of 2012 should it receive government approval.

 

Russia's Ministry of Health and the Federal Tariff Service will not allow prices of drugs on the list to be increased, but the Association of Russian Pharmaceutical Manufacturers (ARPM) has suggested that rises in raw material and labour costs, as well as inflation, have led to a need for price hikes.

 

ARPM has further alleged that, with company's relying on the revenues of drugs on the list, plans to inve

Related News